Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
Qing Zhou, Yi Pan, Xue‐Ning Yang, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1258-1267.e2
Open Access | Times Cited: 12

Showing 12 citing articles:

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial
Chengxiang Yi, Dongliang Bian, Jue Wang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P.L. Saw, Wen‐Zhao Zhong, Rui Fu, et al.
Lung Cancer (2025) Vol. 200, pp. 108076-108076
Open Access
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
Liang Zeng, Huan Yan, Wenjuan Jiang, et al.
Med (2025), pp. 100574-100574
Closed Access
Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study
Yana Qi, Xiaoyang Zhai, Qinhao Xu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, et al.
Cancer Treatment Reviews (2025) Vol. 135, pp. 102918-102918
Open Access
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
Zedao Liu, Zhenlin Yang, Junqi Wu, et al.
Cell (2025)
Open Access
Enhancement of Prognostic Outcomes in Stage III Non-Small Cell Lung Cancer: A Retrospective Study on Neoadjuvant Immuno-Chemotherapy Followed by Definitive Chemo-Radiotherapy
Wenxin Ding, Yechen Ma, Hao Hu, et al.
Translational Oncology (2025) Vol. 56, pp. 102394-102394
Closed Access
Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable Stage IIA-IIIA NSCLC: A Multicenter, Two-Arm, Phase II Exploratory Trial
Shuyu Ji, Zhenxin Sheng, Dongliang Bian, et al.
Research Square (Research Square) (2025)
Closed Access
Next-generation immunotherapy: igniting new hope for lung cancer
Molly Li, Antony C. S. Chan, Kevin Mok, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Neoadjuvant immunotherapy for non-small cell lung cancer: Opportunities and challenges
Junjie Hu, Jing Zhang, Shiyue Wan, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2024) Vol. 2, Iss. 4, pp. 224-239
Open Access
Page 1

Scroll to top